兴科蓉医药（06833）于2026年8月3日发布的股份变动月报显示，截至2026年7月31日，公司法定股本维持在10,000,000,000股普通股，股份面值为每股0.0001港元，注册股本总额为1,000,000港元。报告期初至期末，已发行股份（不含库存股）数量始终为2,032,890,585股，库存股份数为0股，期末已发行股份总数同样保持不变，为2,032,890,585股。
根据月报内容，兴科蓉医药在7月并无新增发行股份、股份回购、注销或库藏股变动。此外，根据2025年5月26日采纳及生效的购股权计划，当月并未发生任何授出、行使或注销，至7月底可行使的期权仍对应203,289,058股普通股。公司确认其已符合相关公众持股比例要求，并且所有发行及股份变动事项均符合香港联合交易所有限公司《上市规则》及其他适用法律法规。截至7月末，兴科蓉医药股本整体保持稳定。
本次公告由公司秘书彭云璐在2026年8月3日签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.